2020 Global Chlamydia Diagnostic Testing Market: US, Europe, Japan-Supplier Shares, 2019-2024 Volume and Sales Segment Forecasts, Competitive Analysis, Emerging Technologies, Instrumentation Review, Opportunities for Suppliers
The report presents a detailed analysis of the Chlamydia diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Chlamydia definition, epidemiology and etiology are reviewed. The report provides the 5-year test volume and sales forecasts by country for the following market segments:
Also, the report examines the market applications of DNA Probes, Monoclonal Antibodies, Immunoassays, IT and other technologies; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies emerging business expansion opportunities, alternative market penetration strategies, market entry barriers and risks, and strategic planning issues and concerns.
Contains 184 pages and 15 tables
- Hospitals
- Commercial/Private Labs
- Physician Offices
- Public Health Labs
Also, the report examines the market applications of DNA Probes, Monoclonal Antibodies, Immunoassays, IT and other technologies; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies emerging business expansion opportunities, alternative market penetration strategies, market entry barriers and risks, and strategic planning issues and concerns.
Contains 184 pages and 15 tables
I. INTRODUCTION
II. WORLDWIDE TEST OVERVIEW, TECHNOLOGIES AND INSTRUMENTATION
A. Background, Diagnostic Tests, Vaccines and Drugs
B. Instrumentation Review: Operating Characteristics, Features and Selling Princes of Leading Infectious Disease Automated and Semi-automated Analyzers
C. Emerging Infectious Disease Diagnostic Technologies
1. Molecular Diagnostics
2. Monoclonal Antibodies
3. Immunoassays
4. Differential Light Scattering
5. Information Technology
6. Artificial Intelligence
7. Liposomes
8. Flow Cytometry
9. Chromatography
10. Diagnostic Imaging
11. Gel Microdroplets
12. Others
D. Personal Testing
III. COUNTRY ANALYSES: SALES AND VOLUME FORECASTS
IV. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES
A. Instrumentation
B. Reagent Kits and Test Systems/Panels
C. Information Technology
D. Auxiliary Products
V. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS
VI. ALTERNATIVE MARKET PENETRATION STRATEGIES
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies for Decentralized Testing Markets
VII. POTENTIAL MARKET ENTRY BARRIERS AND RISKS
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
VIII. COMPETITIVE ASSESSMENTS
Abbott
Affymetrix
Beckman Coulter/Danaher
Becton Dickinson
bioMerieux
Bio-Rad
Cepheid
Diamedix
DiaSorin
Eiken Chemical
Elitech Group
Enzo Biochem
Fujirebio
Grifols
GSK Biologicals
Hologic
Leica Biosystems
Lonza
Ortho-Clinical Diagnostics
PerkinElmer
Qiagen
Roche
Scienion
Sequenom
SeraCare
Siemens Healthineers
Takara Bio
Thermo Fisher
Wako
II. WORLDWIDE TEST OVERVIEW, TECHNOLOGIES AND INSTRUMENTATION
A. Background, Diagnostic Tests, Vaccines and Drugs
B. Instrumentation Review: Operating Characteristics, Features and Selling Princes of Leading Infectious Disease Automated and Semi-automated Analyzers
C. Emerging Infectious Disease Diagnostic Technologies
1. Molecular Diagnostics
2. Monoclonal Antibodies
3. Immunoassays
4. Differential Light Scattering
5. Information Technology
6. Artificial Intelligence
7. Liposomes
8. Flow Cytometry
9. Chromatography
10. Diagnostic Imaging
11. Gel Microdroplets
12. Others
D. Personal Testing
III. COUNTRY ANALYSES: SALES AND VOLUME FORECASTS
IV. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES
A. Instrumentation
B. Reagent Kits and Test Systems/Panels
C. Information Technology
D. Auxiliary Products
V. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS
VI. ALTERNATIVE MARKET PENETRATION STRATEGIES
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies for Decentralized Testing Markets
VII. POTENTIAL MARKET ENTRY BARRIERS AND RISKS
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
VIII. COMPETITIVE ASSESSMENTS
Abbott
Affymetrix
Beckman Coulter/Danaher
Becton Dickinson
bioMerieux
Bio-Rad
Cepheid
Diamedix
DiaSorin
Eiken Chemical
Elitech Group
Enzo Biochem
Fujirebio
Grifols
GSK Biologicals
Hologic
Leica Biosystems
Lonza
Ortho-Clinical Diagnostics
PerkinElmer
Qiagen
Roche
Scienion
Sequenom
SeraCare
Siemens Healthineers
Takara Bio
Thermo Fisher
Wako